UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin

Clinical cancer research, 2017-08, Vol.23 (15), p.4301-4311

2017

Volltextzugriff (PDF)

Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma

Molecular cancer therapeutics, 2018-11, Vol.17 (11), p.2329-2340

2018

Volltextzugriff (PDF)

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells

Oncotarget, 2015-10, Vol.6 (32), p.33397-33409

2015

Volltextzugriff (PDF)

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

Clinical cancer research, 2012-05, Vol.18 (9), p.2638-2647

2012

Volltextzugriff (PDF)

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma

Cancers, 2021-11, Vol.13 (21), p.5504

2021

Volltextzugriff (PDF)

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype

PloS one, 2012-07, Vol.7 (7), p.e40439

2012

Volltextzugriff (PDF)

Safingol (l-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway

Autophagy, 2009-02, Vol.5 (2), p.184-193

2009

Volltextzugriff (PDF)

Abstract 1115: BET bromodomain inhibition synergizes with MEK inhibitors in uveal melanoma

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1115-1115

2021

Volltextzugriff (PDF)

Abstract 1067: PDK-1 targeting with SNS-510 in sarcoma

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1067-1067

2021

Volltextzugriff (PDF)

Abstract 5289: Pre-clinical evaluation of CDK4/6 inhibitor resistance and immunologic modification in liposarcoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5289-5289

2020

Volltextzugriff (PDF)

Homologous recombination repair deficiency as a therapeutic target in sarcoma

Seminars in oncology, 2020-12, Vol.47 (6), p.380-389

2020

Volltextzugriff (PDF)

Abstract 291: Sequential treatment with the Wee1 inhibitor, AZD1775, enhances the effect of trabectedin in the L-sarcomas

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.291-291

2017

Volltextzugriff (PDF)

Abstract 5784: A novel ERK inhibitor in the treatment of uveal melanoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5784-5784

2018

Volltextzugriff (PDF)

Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death

Molecular cancer therapeutics, 2013-05, Vol.12 (5), p.768-776

2013

Volltextzugriff (PDF)

The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1044-1053

2014

Volltextzugriff (PDF)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies

Journal of cellular and molecular medicine, 2023-02, Vol.27 (4), p.587-590

2023

Volltextzugriff (PDF)

Abstract B33: PKC resistance in uveal melanoma is mediated by activation of AKT and reversed by BYL719, the PI3Kα inhibitor

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (14_Supplement), p.B33-B33

2015

Volltextzugriff (PDF)

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

Oncotarget, 2016-01, Vol.7 (4), p.4093-4109

2016

Volltextzugriff (PDF)

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

Cancer research (Chicago, Ill.), 2019-05, Vol.79 (9), p.2415-2425

2019

Volltextzugriff (PDF)

Abstract 2668: Targeting of ERK and HDAC in the treatment of uveal melanoma

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2668-2668

2022

Volltextzugriff (PDF)

The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells

Cancer research communications, 2023-04, Vol.3 (4), p.540-547

2023

Volltextzugriff (PDF)

Abstract 2073: The parp inhibitor olaparib (AZD2281) greatly enances the effect of temozolomide in soft tissue sarcoma cell lines

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2073-2073

2013

Volltextzugriff (PDF)

Abstract 6174: ATX-101, a peptide drug targeting PCNA, enhances the effect of gemcitabine in liposarcoma and leiomyosarcoma

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6174-6174

2023

Volltextzugriff (PDF)

Abstract 4977: Development of small molecule inhibitors of protein interaction with glycosaminoglycans

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4977-4977

2023

Volltextzugriff (PDF)

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Melanoma research, 2021-02, Vol.31 (1), p.27-37

2021

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Cancer Research
(12)
Molecular Cancer Therapeutics
(3)
Oncotarget
(3)
Clinical Cancer Research
(2)
Archives Of Biochemistry And Biophysics
(1)
Autophagy
(1)
Blood
(1)
Cancer Research Communications
(1)
Cancers
(1)
Cytokine
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin

Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma

BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype

Safingol (l-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway

Abstract 1115: BET bromodomain inhibition synergizes with MEK inhibitors in uveal melanoma

Abstract 1067: PDK-1 targeting with SNS-510 in sarcoma

Abstract 5289: Pre-clinical evaluation of CDK4/6 inhibitor resistance and immunologic modification in liposarcoma

Homologous recombination repair deficiency as a therapeutic target in sarcoma

Abstract 291: Sequential treatment with the Wee1 inhibitor, AZD1775, enhances the effect of trabectedin in the L-sarcomas

Abstract 5784: A novel ERK inhibitor in the treatment of uveal melanoma

Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death

The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies

Abstract B33: PKC resistance in uveal melanoma is mediated by activation of AKT and reversed by BYL719, the PI3Kα inhibitor

Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

Abstract 2668: Targeting of ERK and HDAC in the treatment of uveal melanoma

The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells

Abstract 2073: The parp inhibitor olaparib (AZD2281) greatly enances the effect of temozolomide in soft tissue sarcoma cell lines

Abstract 6174: ATX-101, a peptide drug targeting PCNA, enhances the effect of gemcitabine in liposarcoma and leiomyosarcoma

Abstract 4977: Development of small molecule inhibitors of protein interaction with glycosaminoglycans

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Aktive Filter

Suchergebnisse filtern